Akatsuki: Business Alliances, Upgrading Investment Quality, But TRIBE NINE Delays (AKAFF)

mapo Akatsuki Inc. (OTCPK:AKAFF) (3932:TYO) has performed well since we established out position starting around last June. The situation has been that major catalysts have increased visibility of the stock, and the younger management and their major investment plans that will put their unproductive cash to productive uses are credible. The headwind since the jump…

Read More

ADA Price Gains Over 52% in 4 Weeks despite Notable Cardano Network Upgrade Delays

Cardano Foundation CEO Frederik Gregaard recently noted that the development of the smart contract-enabled ecosystem has been slow due to the high academic approach, which has been considered boring but important. Amidst the ongoing altcoin breakout fueled by the optimism revolving around the Bitcoin (BTC) and Ethereum (ETH) exchange-traded funds (ETFs) in the United States,…

Read More

Revolut Appoints New UK CEO amid Licensing Delays

The acquisition of a banking license in the UK could open up new revenue streams for Revolut, allowing the company to generate interest income at a time when interest rates are at multi-year highs.  European fintech giant Revolut has announced the appointment of former Barclays executive Francesca Carlesi as its new UK CEO, signaling a…

Read More

EU delays approval of Novavax’s revised Covid jab

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. EU regulators have delayed a decision to approve Novavax’s variant-tailored Covid-19 vaccine, in a setback for the US-listed biotech which is battling a slump in demand for coronavirus jabs. The European Medicines Agency, which was…

Read More

Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (NASDAQ:IOVA)

Worawee Meepian At a Glance Navigating through regulatory delays and internal investment shifts, Iovance Biotherapeutics (NASDAQ:IOVA) continues to position itself as a frontrunner in T-cell therapies for solid tumors. Since my last “Hold” recommendation, the FDA’s extension of lifileucel’s Priority Review to February 2024 signaled not a roadblock but a procedural hiccup. This delay, paradoxically,…

Read More